Tramadol Hydrochloride
Product Images NDC 71610-392

5 FDA label images from Aphena Pharma Solutions - Tennessee, Llc · Packaging, Regulatory Labels, and Product Appearance

Product Visual Gallery

This gallery contains 5 technical images submitted to the FDA as part of the official labeling for Tramadol Hydrochloride (NDC 71610-392). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Aphena Pharma Solutions - Tennessee, Llc, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Bottle Label 50 mg (71610 0392 15)

Bottle Label 50 mg (71610 0392 15)
Tramadol Hydrochloride USP 50 mg tablet label from Aphena Pharma Solutions - Tennessee, LLC. The label includes NDC 71610-0392-15, specifying 15 tablets per bottle. It advises storage at 20-25 degrees Celsius in a tight-resistant container, warns against use by those with a habit-forming warning, and notes the product is prescription only. Manufactured by Ameal Pharmaceuticals of NY LLC in Brooklyn, NY.*
FDA Label Image

Aphena Pharma Solutions (TN)

FDA Label Image

10 (Tramadol HCl Tablets Usp 1)

10 (Tramadol HCl Tablets Usp 1)
Chemical structure of Tramadol Hydrochloride showing its molecular arrangement with distinct functional groups and hydrochloride salt.*
FDA Label Image

10 (Tramadol HCl Tablets Usp 2)

10 (Tramadol HCl Tablets Usp 2)
A pharmacokinetic concentration-time graph comparing tramadol and its metabolite M1 following single and multiple doses. The x-axis represents time in hours up to 48 hours, and the y-axis shows concentration in ng/mL on a logarithmic scale. Four curves illustrate concentration decline over time for tramadol and M1 after dosing.*
FDA Label Image

10 (Tramadol HCl Tablets Usp 3)

10 (Tramadol HCl Tablets Usp 3)
A line graph titled 'Protocol CAPSS-047 Time to Discontinuation Due to Nausea/Vomiting' showing percent discontinuing on the y-axis and days in double-blind on the x-axis. Two lines compare 10 days to 200 mg/day (red solid line) and 16 days to 200 mg/day (blue dash-dot line) treatment groups over approximately 25 days.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.